在线办公
期刊论坛
主 管
中国人民解放军总医院
主 办
中国人民解放军总医院老年心血管病研究所
中国科技出版传媒股份有限公司
编 辑
中华老年多器官疾病杂志编辑委员会
100853, 北京市复兴路28号
电话:010-66936756
传真:010-66936756
E-mail: zhlndqg@mode301.cn
创刊人 王士雯
总编辑 范利
副总编辑 陈韵岱
执行主编 叶大训
编辑部主任 王雪萍
ISSN 1671-5403
CN 11-4786
创刊时间 2002年
出版周期 月刊
邮发代号 82-408
友情链接
张燕,尚珊珊.茶碱缓释片治疗冠心病患者替格瑞洛相关呼吸困难的临床效果[J].中华老年多器官疾病杂志,2019,18(10):769~772
茶碱缓释片治疗冠心病患者替格瑞洛相关呼吸困难的临床效果
Clinical efficacy of theophylline sustained-release tablets in treatment of tiglillo-related dyspnea in patients with coronary heart disease
投稿时间:2019-05-21  
DOI:10.11915/j.issn.1671-5403.2019.10.166
中文关键词:  茶碱;呼吸困难;替格瑞洛
英文关键词:theophylline; dyspnea; ticagrelor Corresponding author:SHANG Shan-Shan, E-mail:shangss520@163.com〖FL
基金项目:
作者单位E-mail
张燕 陕西省第四人民医院心血管内科,西安 710043  
尚珊珊 陕西省第四人民医院心血管内科,西安 710043 shangss520@163.com 
摘要点击次数: 48
全文下载次数: 57
中文摘要:
      目的 观察茶碱缓释片治疗冠心病患者使用替格瑞洛后出现呼吸困难的临床效果。方法 入选2018年3月至2019年2月陕西省第四人民医院心血管内科服用替格瑞洛后引起呼吸困难但意识清楚、理解力正常的冠心病患者100例,随机数表法分为茶碱组和对照组,每组50例。2组患者均给予抗血小板聚集和他汀类药物以稳定斑块和改善心脏缺血,茶碱组患者在上述治疗基础上给予茶碱缓释片0.1g,对照组患者给予安慰剂维生素C 1g,口服,2次/d,服药1个月。比较2组患者血清腺苷水平、呼吸困难临床症状评分、应用改良版英国医学研究会呼吸困难量表(mMRC)评分、肺功能指标、呼吸衰竭和主要不良心脑血管事件(MACCE)发生率。采用SPSS 19.0统计软件对数据进行分析。结果 治疗后茶碱组相比对照组腺苷[(99.0±17.0)和(160.0±30.0)μg/L]、呼吸困难临床症状评分[(1.2±1.3)和(6.5±1.7)]、mMRC评分[(1.0±0.7)和(2.1±0.4)]、第1秒用力呼气容积(FEV1)占预计值百分比[(85.2±5.3)%和(76.9±7.0)%]、FEV1/用力肺活量[(89.3±3.9)%和(77.9±4.4)%]、呼吸衰竭发生率[2.0%(1/50)和18.8%(8/50)]显著下降,差异均具有统计学意义(P<0.05)。2组患者MACCE发生率差异无统计学意义[6.0%(3/50)和10.0%(5/50),P=0.715]。结论 茶碱缓释片可有效减轻替格瑞洛相关呼吸困难,改善患者通气功能,并且不影响替格瑞洛抗血小板聚集作用。
英文摘要:
      Objective To observe the clinical efficacy of theophylline sustained-release tablets in treatment of dyspnea in coronary heart disease (CHD) patients after administration of ticagrelor. Methods A total of 100 CHD patients who experienced breathing difficulty but had clear consciousness and normal comprehension after taking ticagrelor in the Department of Cardiology of our hospital from March 2018 to February 2019 were enrolled in the study. They were randomly divided into theophylline group and control group, with 50 cases in each group. Both groups were given anti-platelet aggregation and statins to stabilize plaque and improve heart ischemia. Theophylline sustained-release tablets were given to the theophylline group on the basis of the above treatment, 0.1 g orally, vitamin C were given to the control group, 1 g orally, twice a day for 1 month. Serum adenosine levels, score of clinical symptoms of dyspnea, modified British Medical Research Association dyspnea scale (mMRC), pulmonary function indicators, respiratory failure and incidence of major adverse cardiovascular and cerebrovascular events (MACCE) were compared between the 2 groups. SPSS statistics 19.0 was used for data analysis. Results The theophylline group had significantly lower serum adenosine concentration [(99.0±17.0) vs (160.0±30.0)μg/L], score of clinical symptom of dyspnea [(1.2±1.3) vs (6.5±1.7)], mMRC score [(1.0±0.7) vs (2.1±0.4)], forced expiratory volume in 1 second (FEV1) as a percentage of prediction [(85.2±5.3)% vs (76.9±7.0)%],FEV1/forced vital capacity [(89.3±3.9)% vs (77.9±4.4)%], and incidence of respiratory failure [2.0%(1/50) vs 18.8%(8/50)] when compared with the control group (P<0.05). There was no significant difference in the incidence of MACCE between the 2 groups [6.0%(3/50) vs 10.0%(5/50), P=0.715]. Conclusion Theophylline tablets effectively alleviate the dyspnea caused by ticagrelor, improve the ventilatory function, and have no effect on antiplatelet aggregation induced by ticagrelor in the CHD patients.
查看全文    下载PDF阅读器
关闭